Leqembi is a prescription medicine for early-stage Alzheimer’s disease. It’s a monoclonal antibody that helps reduce amyloid plaques in the brain and is the first treatment of its kind approved in the European Union.
Leqembi is a prescription medicine for early-stage Alzheimer’s disease. It’s a monoclonal antibody that helps reduce amyloid plaques in the brain and is the first treatment of its kind approved in the European Union.
